Neurological Response to cART vs. cART plus integrase inhibitor and ccr5 antagonist initiated during acute HIV

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Valcour, Victor G ^a   Spudich, Serena S ^a   Sailasuta, Napapon ^b   Phanuphak, Nittaya ^c   Lerdlum, Sukalaya ^d   Fletcher, James L K ^e   Kroon, Eugene D M B ^f   Jagodzinski, Linda L ^g   Allen, Isabel E ^f   Adams, Collin L ^h   Prueksakaew, Peeriya ⁱ   Slike, Bonnie M ^a   Hellmuth, Joanna M ^a   Kim, Jerome H ^a   Ananworanich, Jintanat ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLINE; CYTOKINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS MARAVIROC PLUS TENOFOVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS RALTEGRAVIR PLUS TENOFOVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR; EFAVIRENZ PLUS LAMIVUDINE PLUS MARAVIROC PLUS TENOFOVIR; EFAVIRENZ PLUS LAMIVUDINE PLUS RALTEGRAVIR PLUS TENOFOVIR; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR; EMTRICITABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; NEOPTERIN; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; BLOOD EXAMINATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; CYTOKINE CEREBROSPINAL FLUID LEVEL; DISEASE DURATION; DISEASE MARKER; FEMALE; GAMMA INTERFERON INDUCIBLE PROTEIN 10 BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY MARKER; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; WHITE MATTER; ADOLESCENT; COMBINATION DRUG THERAPY; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR5; YOUNG ADULT;

EID: 84953255967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142600     Document Type: Article

References (26)

1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012; 206(2):275-82
2. Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011; 204(5):753-60. Epub 2011/08/17. doi: 10.1093/infdis/jir387
3. Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, et al. Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. J Infect Dis. 2013; 207(11):1703-12
4. Peluso M, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Chomchey N, et al. Absence of cerebrospinal fluid signs of neuronal injury before and after immediate antiretroviral therapy in acute HIV infection. Conference on Retrovirus and Opportunistic Infections (CROI); 2014; Seattle, WA
5. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5 (1):69-81
6. Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, et al. HIV DNA reservoir increases risk for cognitive disorders in cART-naive patients. PloS one. 2013; 8(7):e70164
7. Kelly KM, Beck SE, Metcalf Pate KA, Queen SE, Dorsey JL, Adams RJ, et al. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain. Aids. 2013; 27(18):F21-8
8. Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clinical and experimental immunology. 2011; 166(2):184-90
9. Melica G, Canestri A, Peytavin G, Lelievre JD, Bouvier-Alias M, Clavel C, et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. Aids. 2010; 24(13):2130-3
10. Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). Journal of neurovirology. 2014; 20(6):571-82
11. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (New York, NY). 2000; 287 (5453):646-50. Epub 2000/01/29
12. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature medicine. 2010; 16(4):460-5
13. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antiviral therapy. 2012; 17(2):355-64
14. Madeddu G, Menzaghi B, Ricci E, Carenzi L, Martinelli C, di Biagio A, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. Aids. 2012; 26 (18):2412-5
15. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrobial agents and chemotherapy. 2010; 54(12):5156-60
16. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010; 18(2):45-55
17. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids. 2003; 17(13):1871-9
18. Ananworanich J, Fletcher JL, Pinyakorn S, van Griensven F, Vandergeeten C, Schuetz A, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology. 2013; 10:56
19. Heaps J, Valcour V, Chalermchai T, Paul R, Rattanamanee S, Siangphoe U, et al. Development of normative neuropsychological performance in Thailand for the assessment of HIV-associated neurocognitive disorders. Journal of clinical and experimental neuropsychology. 2013; 35(1):1-8
20. Valcour VG, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Ratto-Kim S, Apateerapong W, et al. Neuropsychological abnormalities in patients with dementia in CRF 01AE HIV-1 infection. Neurology. 2007; 68(7):525-7
21. Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PloS one. 2012; 7(11): e49272
22. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol. 1999; 37(8):2557-63
23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995; 57(1):289-300
24. Peluso MJ, editor. Astrocyte and Microglial Activation in Acute and Chronic HIV pre-and post-CART. Conference on Retrovirus and Opportunistic Infections (CROI); 2015; Seattle, WA
25. Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2010; 55(5):590-6
26. Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011; 204(12):1936-45.